Covid-19, Pregnancy
Conditions
Keywords
Covid-19, Pregnancy, antibodies, congenital SARS infection, breast milk
Brief summary
This study aim is to assess impact of COVID-19 infection during pregnancy on outcome of pregnancy, and on developement of the child in early life.
Detailed description
All pregnant women will be tested for serology during each trimester of pregnancy and at delivery, together with a nasal swab. Children born to women with positive sawb or serology will be followed up for 3 years together with a control child born to negative mother. In positive mothers, maternal antibodies at delivery will be characterized, placental transfer will be assessed. Persistence of antibodies in children at the age of 1 month and presence of antibodies in breast milk will be measured. Occurence of premature birth, low birth weight, miscarriage, congenital malformations will be compared in positive and negative mothers. Follow up of children over the first 3 years of life will assess difference in susceptibility to infections and neurological developement in both groups.
Interventions
OTHERno intervention
no intervention
Sponsors
Institute for Medical Immunology (IMI)
Laboratoire Hospitalier Universitaire de Bruxelles (LHUB)
Centre Hospitalier Universitaire Saint Pierre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* For pregnant women, all women who deliver in the CHU St Pierre, with oral consent. * For children follow up: children born to positive mothers and matched controls after written consent
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Outcome of pregnancy | Up to the delivery | Incidence of miscarriage, premature delivery, low birth weight, preeclampsia, chorioamnionitis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Transplacental transfer of antibodies to SARS-CoV-2 | At the delivery | Measure the ratio of cord blood antibodies on maternal antibodies titers |
| To characterize placental alterations related to SARS-CoV-2 infection | At the delivery | Placental histology will be performed in women tested positive for SARS-CoV-2 during pregnancy |
| Prevalence of positive serology to SARS-CoV-2 at delivery | At the delivery | Measure of antibodies in maternal serum at delivery |
| To characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life | Up to 1 month post delivery | Measure of antibodies in cord blood and at the age of 1 month |
| Clinical evolution of the children | Up to 3 years | Occurence of infectious disease, neurological development, growth |
| Presence of maternal antibodies to SARS-CoV-2 in breast milk in breastfeeding mothers | At 1 month post delivery | — |
Countries
Belgium
Outcome results
None listed